AbbVie vs Amgen at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | ABBV | AMGN |
|---|---|---|
| Market cap | $457.23B | $237.42B |
| Price | $258.15 | $436.99 |
| P/E ratio (TTM) | 95.29 | 22.89 |
| P/B ratio (MRQ) | 0 | 20.38 |
| P/S ratio (TTM) | 6.58 | 4.8 |
| Revenue growth (1Y) | 8.57% | 9.92% |
| Return on equity (TTM) | -129.24% | 89.06% |
| Return on invested capital (TTM) | 21.13% | 14.50% |
| Gross margin (TTM) | 73.70% | 72.65% |
| Net margin (TTM) | 5.79% | 22.93% |
| Dividend yield (TTM) | 2.68% | 2.31% |
How they differ
AbbVie is the larger company at $457.23B versus $237.42B — about 1.9x the size.
On trailing earnings, Amgen is the cheaper of the two at 22.89 against 95.29 for AbbVie.
On sales, Amgen is the cheaper of the two at 4.8 against 6.58 for AbbVie.
Amgen leads on revenue growth over the past year, 9.92% against 8.57%.
AbbVie leads on return on invested capital, 21.13% against 14.50%.
AbbVie leads on gross margin, 73.70% against 72.65%.
AbbVie offers the higher yield at 2.68% against 2.31%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving AbbVie or Amgen.